H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas

Description

This is a two cohort Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study will assess the safety of repeated administration of the H3.3K27M specific vaccine in HLA-A2+ children and young adults with H3.3K27M DIPGs and other gliomas.

Study Start Date

November, 01 2016

Estimated Completion Date

November 2020

Interventions

  • Biological: K27M peptide

Study ID

University of California, San Francisco -- PNOC 007

Status

Recruiting

Trial ID

NCT02960230

Study Type

Interventional

Trial Phase

Phase 1

Enrollment Quota

29

Sponsor

University of California, San Francisco

Inclusion Criteria

  • Stratum A:
  • Newly diagnosed children (3-21 years old) with DIPG who are positive for the H3.3K27M mutation (positive testing in CLIA laboratory) that underwent standard radiation therapy. Stratum B: • Newly diagnosed children (3-21 years old) with diagnosis of glioma other than DIPG who are positive for the H3.3K27M mutation (positive testing in CLIA laboratory) including spinal cord gliomas that underwent standard radiation therapy. The following eligibility criteria apply to both Stratum A and B.
  • The patient must test positive for HLA-A2 (human leukocyte antigen A2)(CLIA approved laboratory)
  • The patient must have evaluable disease as defined in section 7.2.1.2
  • The patient must be either off steroids or be on stable dose of dexamethasone (max 0.1 mg/kg/day
  • maximum 4mg/day) at time of enrollment
  • Patients must not have received any prior chemotherapy, immunotherapy or bone marrow transplant for the treatment of their tumor. Prior use of temozolomide during radiation at the standard pediatric dosing or dexamethasone is allowed.
  • Patients must have undergone radiation therapy and surgery as part of their standard of care. o Radiation therapy must have started within 28 days of diagnosis by imaging or surgery, whichever is later.
  • Karnofsky ? 50 for patients ? 16 years of age, and Lansky ? 50 for patients < 16 years of age (See Appendix A). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • The patient must have adequate organ function defined as: Adequate Bone Marrow Function Defined as:
  • Peripheral absolute neutrophil count (ANC) ? 1000/mm3 and
  • Platelet count ? 100,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment). Adequate Renal Function Defined as:
  • Creatinine clearance or radioisotope glomerular filtration rate (GFR) ? 70mL/min/1.73 m2 or
  • A serum creatinine based on age/gender as follows: Age Maximum Serum Creatinine (mg/dL) Male Female 1.
  • 2 years 0.6 0.6 2. to < 6 years 0.8 0.8 6 to < 10 years 1 1 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4 The threshold creatinine values in this table were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the CDC. Adequate Liver Function Defined as:
  • Bilirubin (sum of conjugated + unconjugated) ? 1.5 x upper limit of normal (ULN) for age and
  • SGPT (ALT) ? 110 U/L and
  • Serum albumin ? 2 g/dL. Adequate Neurologic Function Defined as:
  • Patients with seizure disorder may be enrolled if seizure disorder is well controlled.
  • The effects of the H3.3K27M vaccine on the developing human fetus are unknown. For this reason, females of child-bearing potential and men must agree to use adequate contraception. Adequate methods include: hormonal or barrier method of birth control
  • or abstinence prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of study participation.
  • Ability to understand a written informed consent document, and the willingness to sign it. Assent will be obtained when appropriate based on the subjects age.

Exclusion Criteria

  • • Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.
  • Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible.
  • Patients with a history of auto-immune disorder requiring systemic cytotoxic or immunosuppressive therapy are not eligible.

Gender

All

Ages

3 Years to 21 Years

Accepts Healthy Volunteers

No

Study Locations and Contact Information (50)

Study Location Distance Name Phone Email
DanaFarber Cancer Institute - Boston, Massachusetts 2.4 miles Susan Chi MD 617-632-4386 Susan_Chi@dfci.harvard.edu
DanaFarber Cancer Institute - Boston, Massachusetts 2.4 miles Susan Chi MD 617-632-4386 Susan_Chi@dfci.harvard.edu
DanaFarber Cancer Institute - Boston, Massachusetts 2.4 miles Susan Chi MD 617-632-4386 Susan_Chi@dfci.harvard.edu
DanaFarber Cancer Institute - Boston, Massachusetts 2.4 miles Susan Chi MD 617-632-4386 Susan_Chi@dfci.harvard.edu
DanaFarber Cancer Institute - Boston, Massachusetts 2.4 miles Susan Chi MD 617-632-4386 Susan_Chi@dfci.harvard.edu
Childrens Hospital of Philadelphia - Philadelphia, Pennsylvania 270.8 miles Jane Minturn MD PhD 267-426-5026 MINTURN@email.chop.edu
Childrens Hospital of Philadelphia - Philadelphia, Pennsylvania 270.8 miles Jane Minturn MD PhD 267-426-5026 MINTURN@email.chop.edu
Childrens Hospital of Philadelphia - Philadelphia, Pennsylvania 270.8 miles Jane Minturn MD PhD 267-426-5026 MINTURN@email.chop.edu
Childrens Hospital of Philadelphia - Philadelphia, Pennsylvania 270.8 miles Jane Minturn MD PhD 267-426-5026 MINTURN@email.chop.edu
Childrens Hospital of Philadelphia - Philadelphia, Pennsylvania 270.8 miles Jane Minturn MD PhD 267-426-5026 MINTURN@email.chop.edu
Childrens National Medical Center - Washington, District of Columbia 391.7 miles Lindsay Kilburn MD 202-476-3854 lkilburn@cnmc.org
Childrens National Medical Center - Washington, District of Columbia 391.7 miles Lindsay Kilburn MD 202-476-3854 lkilburn@cnmc.org
Childrens National Medical Center - Washington, District of Columbia 391.7 miles Lindsay Kilburn MD 202-476-3854 lkilburn@cnmc.org
Childrens National Medical Center - Washington, District of Columbia 391.7 miles Lindsay Kilburn MD 202-476-3854 lkilburn@cnmc.org
Childrens National Medical Center - Washington, District of Columbia 391.7 miles Lindsay Kilburn MD 202-476-3854 lkilburn@cnmc.org
Ann Robert H Lurie Childrens Hospital of Chicago - Chicago, Illinois 847.9 miles Stewart Goldman MD 312-227-4873 None
Ann Robert H Lurie Childrens Hospital of Chicago - Chicago, Illinois 847.9 miles Stewart Goldman MD 312-227-4873 None
Ann Robert H Lurie Childrens Hospital of Chicago - Chicago, Illinois 847.9 miles Stewart Goldman MD 312-227-4873 None
Ann Robert H Lurie Childrens Hospital of Chicago - Chicago, Illinois 847.9 miles Stewart Goldman MD 312-227-4873 None
Ann Robert H Lurie Childrens Hospital of Chicago - Chicago, Illinois 847.9 miles Stewart Goldman MD 312-227-4873 None
St Louis Childrens Hospital - Saint Louis, Missouri 1,039.5 miles Karen Gauvain MD 314-454-2002 gauvain_k@kids.wustl.edu
St Louis Childrens Hospital - Saint Louis, Missouri 1,039.5 miles Karen Gauvain MD 314-454-2002 gauvain_k@kids.wustl.edu
St Louis Childrens Hospital - Saint Louis, Missouri 1,039.5 miles Karen Gauvain MD 314-454-2002 gauvain_k@kids.wustl.edu
St Louis Childrens Hospital - Saint Louis, Missouri 1,039.5 miles Karen Gauvain MD 314-454-2002 gauvain_k@kids.wustl.edu
St Louis Childrens Hospital - Saint Louis, Missouri 1,039.5 miles Karen Gauvain MD 314-454-2002 gauvain_k@kids.wustl.edu
St Jude Childrens Research Hospital - Memphis, Tennessee 1,134.7 miles Amar Gajjar MD 901-595-2615 Amar.Gajjar@stjude.org
St Jude Childrens Research Hospital - Memphis, Tennessee 1,134.7 miles Amar Gajjar MD 901-595-2615 Amar.Gajjar@stjude.org
St Jude Childrens Research Hospital - Memphis, Tennessee 1,134.7 miles Amar Gajjar MD 901-595-2615 Amar.Gajjar@stjude.org
St Jude Childrens Research Hospital - Memphis, Tennessee 1,134.7 miles Amar Gajjar MD 901-595-2615 Amar.Gajjar@stjude.org
St Jude Childrens Research Hospital - Memphis, Tennessee 1,134.7 miles Amar Gajjar MD 901-595-2615 Amar.Gajjar@stjude.org
Seattle Childrens Hospital - Seattle, Washington 2,487.2 miles Sarah Leary MD 206-987-2106 sarah.leary@seattlechildrens.org
Seattle Childrens Hospital - Seattle, Washington 2,487.2 miles Sarah Leary MD 206-987-2106 sarah.leary@seattlechildrens.org
Seattle Childrens Hospital - Seattle, Washington 2,487.2 miles Sarah Leary MD 206-987-2106 sarah.leary@seattlechildrens.org
Seattle Childrens Hospital - Seattle, Washington 2,487.2 miles Sarah Leary MD 206-987-2106 sarah.leary@seattlechildrens.org
Seattle Childrens Hospital - Seattle, Washington 2,487.2 miles Sarah Leary MD 206-987-2106 sarah.leary@seattlechildrens.org
Oregon Health Science University - Portland, Oregon 2,538.3 miles Kellie Nazemi MD 503-494-1543 nazemik@ohsu.edu
Oregon Health Science University - Portland, Oregon 2,538.3 miles Kellie Nazemi MD 503-494-1543 nazemik@ohsu.edu
Oregon Health Science University - Portland, Oregon 2,538.3 miles Kellie Nazemi MD 503-494-1543 nazemik@ohsu.edu
Oregon Health Science University - Portland, Oregon 2,538.3 miles Kellie Nazemi MD 503-494-1543 nazemik@ohsu.edu
Oregon Health Science University - Portland, Oregon 2,538.3 miles Kellie Nazemi MD 503-494-1543 nazemik@ohsu.edu
Rady Childrens HospitalSan Diego - San Diego, California 2,579.1 miles Jennifer Elster MD 858-576-1600 jelster@rchsd.org
Rady Childrens HospitalSan Diego - San Diego, California 2,579.1 miles Jennifer Elster MD 858-576-1600 jelster@rchsd.org
Rady Childrens HospitalSan Diego - San Diego, California 2,579.1 miles Jennifer Elster MD 858-576-1600 jelster@rchsd.org
Rady Childrens HospitalSan Diego - San Diego, California 2,579.1 miles Jennifer Elster MD 858-576-1600 jelster@rchsd.org
Rady Childrens HospitalSan Diego - San Diego, California 2,579.1 miles Jennifer Elster MD 858-576-1600 jelster@rchsd.org
UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco, California 2,696.4 miles Sabine Mueller MD 415-476-3831 sabine.mueller@ucsf.edu
UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco, California 2,696.4 miles Sabine Mueller MD 415-476-3831 sabine.mueller@ucsf.edu
UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco, California 2,696.4 miles Sabine Mueller MD 415-476-3831 sabine.mueller@ucsf.edu
UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco, California 2,696.4 miles Sabine Mueller MD 415-476-3831 sabine.mueller@ucsf.edu
UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco, California 2,696.4 miles Sabine Mueller MD 415-476-3831 sabine.mueller@ucsf.edu

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.